Polymorphism of XRCC1 predicts overall survival of gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population

This publication has 31 references indexed in Scilit:

• Quality of life in patients with advanced gastric cancer: a randomized trial comparing docetaxel, cisplatin, 5-FU (TCF) with epirubicin, cisplatin, 5-FU (ECF)
  BMC Cancer, 2006
• Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group
  Journal of Clinical Oncology, 2006
• DNA Repair by ERCC1 in Non–Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy
  New England Journal of Medicine, 2006
• Predicting the outcome of chemotherapy for lung cancer
  Current Opinion in Pharmacology, 2006
• Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF
  British Journal of Cancer, 2005
• XRCC1 is required for DNA single-strand break repair in human cells
  Nucleic Acids Research, 2005
• ABCC5, ERCC2, XPA and XRCC1 transcript abundance levels correlate with cisplatin chemoresistance in non-small cell lung cancer cell lines
  Molecular Cancer, 2005
• XPD and XRCC1 Genetic Polymorphisms Are Prognostic Factors in Advanced Non—Small-Cell Lung Cancer Patients Treated With Platinum Chemotherapy
  Journal of Clinical Oncology, 2004
• Cancer pharmacogenetics
  British Journal of Cancer, 2004
• Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution
  Carcinogenesis, 1998